AR021106A1 -
COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES
- Google Patents
COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & CofiledCriticalSearle & Co
Publication of AR021106A1publicationCriticalpatent/AR021106A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se describen combinaciones de un inhibidor ACE y un antagonista del receptor de aldosterona para su uso en el tratamiento de trastornos circulatorios. Sonde particular interés las terapias con captopril, enalapril o lisinopril co-administradas con espironolactona. Esta coterapia será de particular utilidad parareducir el índice de mortalidad o la cantidad de internaciones no fatales o para prevenir el avance de la insuficiencia cardíaca congestiva en pacientes conenfermedades cardiovasculares.Combinations of an ACE inhibitor and an aldosterone receptor antagonist are described for use in the treatment of circulatory disorders. Of particular interest are therapies with captopril, enalapril or lisinopril co-administered with spironolactone. This therapy will be particularly useful to reduce the death rate or the number of non-fatal hospitalizations or to prevent the progression of congestive heart failure in patients with cardiovascular disease.
ARP9901056231998-11-061999-11-05
COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES
AR021106A1
(en)
COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES
COMBINED THERAPY WITH THE USE OF ANGIOTENZIN CONVERSION AND ANTAGONIST ALDOSTERONE ENVIRONMENTAL INHIBITOR TO REDUCE INCIDENCE AND MORTALITY IN CARDIOVASCULAR DISEASES
DERIVATIVES 1,2,3,4-TETRAGIDROPYRROLO [1,2-A] PIRAZIN-6-CARBOXAMIDES AND 2,3,4,5-TETRAHYDROPYRROLO [1,2-a] [1,4] -DIAZEPIN-7-CARBOXAMIDES , THEIR RECEIVING AND THEIR APPLICATION IN THERAPY
Combination therapy of anti-biotin conversion enzyme inhibitor and amount of reduced side effect of aldosterone antagonist for the treatment of cardiovascular disease
COMBINED THERAPY OF AN ANGIOTENSIN CONVERTER ENZYME INHIBITOR AND AN ALDOSTERONE ANTAGONIST TO REDUCE MORBILITY AND MORTALITY BY CARDIOVASCULAR DISEASES